TrialsgrambetaRCTs are beautiful

TOPCAT

2014

Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist

In 3,445 patients with HFpEF (EF ≥ 45%), spironolactone did not significantly reduce cardiovascular death, aborted cardiac arrest, or heart-failure hospitalisation compared with placebo.

Result

Efficacy: Composite of cardiovascular death, aborted cardiac arrest, or heart-failure hospitalisationHR 0.89 (95% CI 0.77-1.04) · P = 0.14

Below 1 favours spironolactone, above 1 favours placebo.

Event rates
Absolute difference
1.8 points

The absolute difference is derived from the event rates.

Also reported: Neutral: HF hospitalisation alone reduced (HR 0.83, 95% CI 0.69-0.99).

Original publication
Subtopic
MRA
Design
Double-blind placebo-controlled RCT
Relevance
Important: one of several pillars.
Source
Pitt B, et al. N Engl J Med. 2014;370(15):1383-1392.doi 10.1056/NEJMoa1313731

Discussion & critique

Marked regional heterogeneity (very low event rates and doubtful drug exposure in Russia/Georgia) undermined the null result; post-hoc Americas data suggest benefit. Guidelines give spironolactone a weak/conditional recommendation in HFpEF.

Discussed in podcasts